Abstract:Abstract Background The CRISPR-Cas12a (formerly Cpf1) system is a versatile gene-editing tool with properties distinct from the broadly used Cas9 system. Features such as recognition of T-rich protospacer-adjacent motif (PAM) and generation of sticky breaks, as well as amenability for multiplex editing in a single crRNA and lower off-target nuclease activity, broaden the targeting scope of available tools and enable more accurate genome editing. However, the widespread use of the nuclease for gene editing, especially in clinical applications, is hindered by insufficient activity and specificity despite previous efforts to improve the system. Currently reported Cas12a variants achieve high activity with a compromise of specificity. Here, we used structure-guided protein engineering to improve both editing efficiency and targeting accuracy of Acidaminococcus sp. Cas12a ( As Cas12a) and Lachnospiraceae bacterium Cas12a ( Lb Cas12a). Results We created new As Cas12a variant termed “ As Cas12a-Plus” with increased activity (1.5~2.0-fold improvement) and specificity (reducing off-targets from 29 to 23 and specificity index increased from 92% to 94% with 33 sgRNAs), and this property was retained in multiplex editing and transcriptional activation. When used to disrupt the oncogenic BRAF V600E mutant, As Cas12a-Plus showed less off-target activity while maintaining comparable editing efficiency and BRAF V600E cancer cell killing. By introducing the corresponding substitutions into Lb Cas12a, we also generated Lb Cas12a-Plus (activity improved ~1.1-fold and off-targets decreased from 20 to 12 while specificity index increased from 78% to 89% with 15 sgRNAs), suggesting this strategy may be generally applicable across Cas12a orthologs. We compared Cas12a-Plus, other variants described in this study, and the reported enCas12a-HF, enCas12a, and Cas12a-ultra, and found that Cas12a-Plus outperformed other variants with a good balance for enhanced activity and improved specificity. Conclusions Our discoveries provide alternative As Cas12a and Lb Cas12a variants with high specificity and activity, which expand the gene-editing toolbox and can be more suitable for clinical applications.

Rationally engineered Cas9 nucleases with improved specificity

Deleting Specific Residues From the HNH Linkers Creates A CRISPR-SpCas9 Variant With High Fidelity and Efficiency

Fine-Tuning Cas9 Activity with a Cognate Inhibitor AcrIIA4 to Improve Genome Editing in <i>Streptomyces</i>

Computationally Engineered CRISPR-SpyCas9 High-Fidelity Variants with Improved Specificity and Reduced Non-specific DNA Damage

Target-matched increased fidelity SpCas9 variants can edit any target without genome-wide off-target effects

Rationally engineered Staphylococcus aureus Cas9 nucleases with high genome-wide specificity

A cleavage rule for selection of increased-fidelity SpCas9 variants with high efficiency and no detectable off-targets

High-throughput in vitro specificity profiling of natural and high-fidelity CRISPR-Cas9 variants

Engineered CRISPR-Cas9 nuclease with expanded targeting space

Crossing enhanced and high fidelity SpCas9 nucleases to optimize specificity and cleavage

Engineered CRISPR-Cas9 nucleases with altered PAM specificities

Engineered Cas12a-Plus nuclease enables gene editing with enhanced activity and specificity

Recent Advances in Improving Gene-Editing Specificity through CRISPR–Cas9 Nuclease Engineering

Engineering Cas9: next generation of genomic editors

Quantifying Protein-Nucleic Acid Interactions for Engineering Useful CRISPR-Cas9 Genome-Editing Variants

Structure-based optimization and design of CRISPR protein xCas9

Engineered Campylobacter jejuni Cas9 variant with enhanced activity and broader targeting range

Genome editing with natural and engineered CjCas9 orthologs

A Type II-B Cas9 nuclease with minimized off-targets and reduced chromosomal translocations in vivo

Structural insights into a high fidelity variant of SpCas9

Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants